Drotrecogin alfa
- Generic Name
- Drotrecogin alfa
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 98530-76-8
- Unique Ingredient Identifier
- JGH8MYC891
- Background
Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. Drotrecogin alfa was withdrawn from the market after a major study indicated that it was not effective in improving outcomes in patients with sepsis.
- Indication
For reduction of mortality in patients with severe sepsis.
- Associated Conditions
- -
- Associated Therapies
- -
Star Therapeutics' VGA039 gains FDA fast track status
The 'fully human' IgG4 antibody targets Protein S to balance blood clotting, offering a universal haemostatic therapy for bleeding disorders. It's the first subcutaneous therapy for all VWD types, with a convenient dosing regimen. Phase I trial VIVID 1 showed favorable safety. Star Therapeutics, backed by life sciences investors, aims to accelerate VGA039's development for VWD treatment.
Vega Therapeutics Receives FDA Orphan Drug Designation for VGA039, a Novel Antibody Therapy for von Willebrand Disease
Vega Therapeutics received FDA orphan drug designation for VGA039, a novel antibody therapy for von Willebrand disease (VWD), targeting Protein S to enhance clot formation. VGA039, in Phase 1 trials, aims to reduce treatment burden and improve patient outcomes in VWD and other bleeding disorders.
Related Clinical Trials:
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath